Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

126
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
126
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

332
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
332
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

170
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of Rb and p53 Expression in a Case of CM2B4 Negative Merkel Cell Carcinoma In Situ Associated With Squamous Dysplasia.

Journal of cutaneous pathology·2026
Same author

The Need for Standardized Leadership Training in Undergraduate Medical Education.

Medical science educator·2026
Same author

Standardized Color-Coded Inking Protocol to Reduce Specimen Misidentification in Biopsies and Mohs Surgery.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2025
Same author

The Influence of Dietary Factors on Melanoma Development and Progression: A Comprehensive Review.

Nutrients·2025
Same author

Treatment of Necrobiotic Xanthogranuloma With Upadacitinib: A Case Report.

International journal of dermatology·2025
Same author

Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment.

Biomolecules·2025

Related Experiment Video

Updated: May 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.7K

Roflumilast for the Treatment of Seborrheic Dermatitis: A Review.

Austinn C Miller1,2, Abigail E Watson3, Marc J Inglese1,2,3

  • 1University of Central Florida/HCA Healthcare Consortium, Tallahassee, FL, USA.

Skin Therapy Letter
|March 12, 2025
PubMed
Summary

Roflumilast 0.3% foam offers a new, non-steroidal option for treating seborrheic dermatitis (SD). This review examines its safety and effectiveness for this chronic inflammatory skin condition.

Keywords:
PDE-4 inhibitorroflumilastseborrheic dermatitistreatment

More Related Videos

Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth
11:06

Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth

Published on: April 23, 2019

7.7K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K

Related Experiment Videos

Last Updated: May 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.7K
Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth
11:06

Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth

Published on: April 23, 2019

7.7K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K

Area of Science:

  • Dermatology
  • Inflammatory Skin Disorders
  • Pharmacology

Background:

  • Seborrheic dermatitis (SD) is a chronic inflammatory skin condition affecting sebaceous gland-rich areas.
  • SD development involves factors like Malassezia colonization, immune response, and environmental triggers.
  • Current treatments include topical antifungals, corticosteroids, and calcineurin inhibitors.

Purpose of the Study:

  • To review the safety and efficacy of roflumilast 0.3% foam for seborrheic dermatitis.
  • To evaluate a novel non-steroidal treatment option for SD.

Main Methods:

  • Literature review of clinical trials and studies on roflumilast 0.3% foam.
  • Analysis of safety and efficacy data from recent research.

Main Results:

  • Clinical trials demonstrate the efficacy of roflumilast 0.3% foam in treating SD.
  • The non-steroidal foam presents a validated therapeutic option.

Conclusions:

  • Roflumilast 0.3% foam shows promise as a safe and effective treatment for seborrheic dermatitis.
  • This foam represents a significant advancement in SD management.